Ding Suet Lee Shirley, Kumar Suresh, Mok Pooi Ling
Department of Biomedical Science, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Int J Mol Sci. 2017 Jul 28;18(8):1406. doi: 10.3390/ijms18081406.
The use of multipotent mesenchymal stem cells (MSCs) has been reported as promising for the treatment of numerous degenerative disorders including the eye. In retinal degenerative diseases, MSCs exhibit the potential to regenerate into retinal neurons and retinal pigmented epithelial cells in both in vitro and in vivo studies. Delivery of MSCs was found to improve retinal morphology and function and delay retinal degeneration. In this review, we revisit the therapeutic role of MSCs in the diseased eye. Furthermore, we reveal the possible cellular mechanisms and identify the associated signaling pathways of MSCs in reversing the pathological conditions of various ocular disorders such as age-related macular degeneration (AMD), retinitis pigmentosa, diabetic retinopathy, and glaucoma. Current stem cell treatment can be dispensed as an independent cell treatment format or with the combination of other approaches. Hence, the improvement of the treatment strategy is largely subjected by our understanding of MSCs mechanism of action.
据报道,多能间充质干细胞(MSCs)有望用于治疗包括眼部疾病在内的多种退行性疾病。在视网膜退行性疾病中,体外和体内研究均表明,MSCs具有再生为视网膜神经元和视网膜色素上皮细胞的潜力。研究发现,递送MSCs可改善视网膜形态和功能,并延缓视网膜变性。在本综述中,我们重新审视了MSCs在患病眼中的治疗作用。此外,我们揭示了MSCs在逆转各种眼部疾病(如年龄相关性黄斑变性(AMD)、色素性视网膜炎、糖尿病性视网膜病变和青光眼)病理状况时可能的细胞机制,并确定了相关信号通路。目前的干细胞治疗可以作为一种独立的细胞治疗形式,也可以与其他方法联合使用。因此,治疗策略的改进很大程度上取决于我们对MSCs作用机制的理解。